This policy brief addresses the Trump Administration’s revived Most Favored Nation pricing push, including a 2025 executive order, manufacturer agreements, and proposed GLOBE/GUARD payment models). IVI cautions that importing foreign price benchmarks risks reducing healthcare value to price alone, potentially harming access and innovation unless it is paired with patient-centered, transparent value assessment.
